COCP 2,09$ (+56%)

Corona-Hype

• Umsatz 0,5 Mio. $ (alles für Q3/19)
  
• Verlust 1,8 Mio. $
  
• Cash 6 Mio. $
  
• MK 87 Mio. $
  

www.cocrystalpharma.com/news/...-third-quarter-2019-financial

Dann kam Corona, der Kurs stieg, das Management zog ein Offering durch:

• 3,5 Mio. neue Aktien zu je 0,63$ = 2,2 Mio. $
  

www.cocrystalpharma.com/news/...ounces-closing-of-2-2-million

Mal sehen, wann die nächste Kapitalerhöhung kommt...

$COCP. Current Report Filing (8-k)

ih.advfn.com/stock-market/NASDAQ/.../current-report-filing-8-k

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2020

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)



Delaware 001-38418 35-2528215
(State or other Jurisdiction

of Incorporation)


(Commission

File Number)


(IRS Employer

Identification No.)



19805 N. Creek Parkway

Bothell, WA

98011
(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (786) 459-1831


(Former name or former address, if changed since last report.):

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).



Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol(s) Name of each exchange on which registered
Common Stock COCP
The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)


Item 7.01 Regulation FD Disclosure.



On March 4, 2020, Cocrystal Pharma, Inc. (the “Company”) posted a presentation to its website. A copy of the Company’s presentation is being furnished as Exhibit 99.1 hereto.



The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, or the Exchange Act.



Item 9.01. Financial Statements and Exhibits.

(d)
Exhibit No.


Description.


99.1 Investor Presentation dated March 2020


SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Cocrystal Pharma, Inc.

Dated: March 4, 2020 By: /s/ James Martin
James Martin
Chief Financial Officer

March 6, 2020
finance.yahoo.com/news/...ounces-plans-advance-210110576.html

... Given the global threat of COVID1-9, our primary goal is to advance our Coronavirus program into preclinical development.

Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

www.globenewswire.com/news-release/2020/03/...es-for-2020.html

-50% seit #1

dabei, schauen wir mal wo die Reise hingeht, GLTA.

ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1

Cocrystal Pharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Cocrystal Pharma with a Buy rating and $5 price target. The company utilizes a "unique" proprietary co-crystallization platform to design novel small molecules aimed at well-known molecular targets within multiple viruses, Selvaraju tells investors in a research note. The analyst assumes a partnership to commercialize CC-31244, with royalties of 12%-20% payable to Cocrystal on net sales of the drug.

Read more at:
thefly.com/landingPageNews.php?id=3122041

www.marketwatch.com/investing/stock/cocp

www.marketwatch.com/investing/stock/cocp

Riecht nach News, wieder auf das richtige Pferd gesetzt.

Hallo zusammen,

möglich das es sich um diese Meldung von gestern handelt ?

eurekalert.org/pub_releases/2020-08/ksu-nps080320.php

Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal

www.cocrystalpharma.com/news/...-publication-by-collaborators

15 Mio. $ Offering

• 14,3 Mio. neue Aktien zu je 1,05$
  

seekingalpha.com/news/...a-raises-bought-deal-offering-to-15m

content.equisolve.net/...stor+Presentation_September+2020.pdf

Denke es hat mit dem TipRanks Artikel zu tun:

Billionaire Steven Cohen Pulls the Trigger on These 2 Penny Stocks

finance.yahoo.com/news/...-cohen-pulls-trigger-144600355.html

www.marketwatch.com/investing/stock/cocp

www.marketwatch.com/investing/stock/cocp

Für einen Freitag ein schöner Endkurs, die Reise geht weiter, imo.

ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1

Compound for Further Development Against Coronaviruses

CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2

www.cocrystalpharma.com/news/...cts-lead-compound-for-further

www.marketwatch.com/investing/stock/cocp

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement


... announces it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now solely responsible for further development of the influenza A/B antiviral compounds that were discovered using Cocrystal’s unique structure-based technologies and Nobel Prize-winning expertise.


... Under the agreement announced in January 2019, Merck had an option for Cocrystal to perform up to 12 months of additional work if the initial two years of collaboration did not progress as expected. We are pleased our collaboration achieved its goals within the timeline and that there is no need for Merck to exercise the option. As this program advances, Merck is now responsible for funding continued development of the compounds.”


... Developing new, effective influenza antivirals represents a significant unmet worldwide medical need and is integral to our infectious diseases R&D strategy,” said Daria Hazuda, Ph.D., Vice President, Infectious Diseases Discovery, Merck Research Laboratories and Chief Scientific Officer, Merck Exploratory Science Center. “We are pleased with the progress under our collaboration with Cocrystal and look forward to further development of the antiviral agents in the influenza A/B program at Merck.”


www.cocrystalpharma.com/news/...ther-development-of-influenza

Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs

finance.yahoo.com/news/...ma-provides-covid-19-120000496.html

“We believe that, due to their novel mechanism of action, our protease inhibitors are likely to be effective against new variants of SARS-CoV-2. This may include the recent variants first identified in the United Kingdom, South Africa, Brazil and India, which may be more contagious forms of the virus and may evade immunity produced by vaccines or previous infection,” he added.

... Cocrystal’s approach to drug discovery could provide a solution for designing antivirals for use against a range of viruses, including coronaviruses, with limited off-target interaction.

Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

... 26,000,000 shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about May 7, 2021, subject to satisfaction of customary closing...

finance.yahoo.com/news/...announces-40-million-224100461.html

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

www.cocrystalpharma.com/news/...2-3cl-protease-lead-cdi-45205

20.08.21:
40.000 shares zu $1.03

www.insidercow.com

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

finance.yahoo.com/news/...ustralian-regulatory-124900491.html

Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

…SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis.

…Our current focus is on advancing these SARS-CoV-2 main protease inhibitors toward clinical development as a potential oral treatment for patients with COVID-19,” he added. “We now have additional opportunities with these same protease inhibitors for future programs that target other areas of high unmet medical need.”

www.cocrystalpharma.com/news/...ov-2-main-protease-inhibitors

Vom 22.12.2021

Cocrystal Pharma’s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

...We believe that, due to their novel mechanism of action, our protease inhibitors will be effective against newly emerging SARS-CoV-2 variants. We are also highly encouraged by promising safety profiles of our SARS-CoV-2 oral protease inhibitors from 7-day mouse oral dosing toxicity studies. Our goal is to rapidly advance two protease inhibitors into first-in-human studies as rapidly as possible.”

www.cocrystalpharma.com/news/...-oral-and-intranasalpulmonary

CDI-45205 is one of three COVID-19 programs underway at Cocrystal. In the second COVID-19 program, the Company plans to begin a Phase 1 study also in 2022 with an orally administered main protease inhibitor. In the third COVID-19 program, Cocrystal is using its unique structure-based technology platform to discover replication inhibitors for oral administration.

“Our COVID-19 programs feature novel inhibitors that are specifically designed to block viral replication of SARS-CoV-2,” said James Martin, Cocrystal’s CFO and interim co-CEO. “Our inhibitors have shown antiviral activity against various SARS-CoV-2 variants to date, including the Alpha, Beta, Gamma and Delta variants, and now even the Omicron variant. CDI-45205 is not a quick-to-market repurposed drug. Because of its design, we remain highly confident in the broad-spectrum antiviral ability of our compound CDI-45205 in addressing SARS-CoV-2 and variants.”

www.cocrystalpharma.com/news/...-guidance-to-advance-clinical

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

•Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity against all variants of concern including Omicron

•Clinical trials with oral program and CDI-45204 inhalation/pulmonary-delivered COVID-19 antiviral candidates expected to begin in 2022

ir.cocrystalpharma.com/press-releases/...iral-drug-candidates

Studie
ir.cocrystalpharma.com/press-releases/detail/152

ir.cocrystalpharma.com/press-releases/detail/157